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Evidence-based practice requires trans-
lating research findings into clinical and
policy decision making. Clinical practice
guidelines (CPGs) serve this purpose by
evaluating evidence and making recom-
mendations about therapeutic and diag-
nostic interventions and clinical manage-
ment strategies. Systematic reviews are
considered the best available evidence and
are often used in the development of
CPGs [1,2]. Since guideline development
involves an assessment of the overall
quality of evidence and complex balancing
of trade-offs between the important ben-
efits and harms of any given intervention,
arbitrariness, value judgements, and sub-
jectivity ultimately come into play in the
guideline development process and associ-
ated recommendations [3]. In order to
minimize cognitive bias in interpreting
evidence and make the inherently subjec-
tive process more transparent and consis-
tent, CPGs have traditionally employed
formal systems or frameworks to under-
stand and grade the quality of the body of
evidence and strength of recommenda-
tions [4,5].
One such framework is the grading
quality of evidence and strength of recom-
mendations (GRADE), which is common-
ly used by guideline panels in deriving
health care recommendations. GRADE
was developed to overcome some of the
deficiencies of earlier efforts [6]. GRADE
defines the quality of evidence as the
collective level of confidence guideline
developers have about the validity of
estimates of benefits and harms for any
given intervention, and the strength of
guideline recommendation as the extent of
collective confidence that adherence to the
recommendation will do more good than
harm [7]. It urges guideline developers to
consider all important patient outcomes of
benefit and harm, to systematically evalu-
ate the quality of their estimates, and to
assess the trade-offs between evidence of
benefits and harms, the preferences and
values placed by patients on outcomes, the
opportunity cost associated with the rec-
ommendation, and the feasibility of rec-
ommendations given a clinical setting
before formulating guideline recommen-
dations. Details of the GRADE approach
have been published elsewhere [8].
In a new Policy Forum published in this
issue of PLoS Medicine,K a v a n a g h[ 9 ]
questions the external consistency of the
GRADE framework by comparing the
Surviving Sepsis Campaign (SSC) guideline
recommendations developed in 2004 and
updated in 2008. Moreover, Kavanagh
expresses his concerns on the processes of
the GRADE development and its formal
validation. Had we likened the GRADE
approach to an instrument or a health
profile built on discrete logic to capture
evidence, we would have concurred with
some of Kavanagh’s criticism of GRADE.
However, we see GRADE as a framework
uncovering implicit subjectivity and invok-
ing a systematic, explicit, judicious, and
transparent approach to interpreting, as
opposed to ‘‘capturing’’ evidence. It reveals
how values are assigned to judgments, but
what values are assigned it does not dictate
simply because it cannot dictate. Below we
firstpresentourconcernaboutoneaspectof
the GRADE framework and then our
perspective on the various criticisms of it.
One Concern about the GRADE
Approach
It is arguable that guideline recommen-
dations should be based on cost-effective-
ness and opportunity cost analyses. These
comparative economic analyses implicitly
assume, and therefore do not question,
that the allocated health care budget is
based on sound evidence to influence
guideline recommendations sensibly. In
other words, the analyses are supposed to
generate reasonable health care policies
within a limited budget. However, the
appropriateness of the health care budget
itself is not established, a priori.
Although the GRADE framework rec-
ognizes that guideline panels may legiti-
mately ignore consideration of cost in terms
of comparative resource use analysis in
developing recommendations, the fra-
mework appears to recommend it. This
recommendation would be more meaning-
ful if there was accompanying evidence
about the appropriateness of allocation of
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Linked Research Article
This Perspective discusses the fol-
lowing new Policy Forum published
in PLoS Medicine:
Kavanagh B (2009) The GRADE
System for Rating Clinical Guide-
lines. PLoS Med 6(9): e1000094.
doi:10.1371/journal.pmed.1000094
Brian Kavanagh critiques the GRADE
system of grading guidelines, argu-
ing that even though it has evolved
through the Evidence-Based Medi-
cine movement, there is no evi-
dence that GRADE itself is reliable.
PLoS Medicine | www.plosmedicine.org 1 September 2009 | Volume 6 | Issue 9 | e1000151resources towards healthcare in general
and a given healthcare discipline in partic-
ular.
Criticisms of GRADE: Our
Perspective
N GRADE is flawed because some guide-
line recommendations are inconsistent
with the evidence, or there is lack of
clarity in how they were reached
Invalid guideline recommendations
coming out of CPGs using the GRADE
framework do not necessarily imply a
problem with GRADE itself. The frame-
work might have been used inappropriate-
ly. For example, lack of transparent report-
ing of how GRADE led to the reco-
mmendation, or poor judgment of the
quality of evidence, importance of the
outcomes for which evidence was found,
or benefit-harm trade-offs may be misin-
terpreted as a flaw with GRADE. Sound
use of the GRADE approach by guideline
panels is only possible when they are
multidisciplinary and include clinical con-
tent experts, methodologists, and patients’
representatives and have no conflict of
interest [10]. Although these are general
recommendations, it is unclear whether
guideline developers actually ensure a
multidisciplinary composition of their pan-
els. For example, eight of the 17 members
of the 2007 CPG panel recommending that
aprotinin should be used during high-risk
cardiac surgery had a financial relationship
with the drug manufacturer [11]. Even
though evidence of harms of the drug was
available from observational studies, the
recommendation ignored it. It is to be
noted, however, that the panel did not use
the GRADE approach.
N Quality of evidence alone determines
the strength of recommendation
This is incorrect. Recommendations
also factor in the potential impact or
consequences of the available evidence.
Therefore, using GRADE, low quality of
evidence can lead to strong recommenda-
tion(s) occasionally. For example, evidence
from a hypothetical short-term random-
ized controlled trial with serious risk of
bias showing modest benefit of an inter-
vention without serious harms on surro-
gate outcomes for a fatal infectious disease
in a Chinese population might be consid-
ered of low quality for whites. However, in
a situation of a pandemic, strong recom-
mendation for the intervention in this
population is plausible. Another example
for a strong recommendation against a
treatment may be that of cerivastatin,
which was withdrawn from the market due
to concerns of drug-related rhabdomyoly-
sis and renal failure based on post-
marketing surveillance data [12]. Had a
GRADE approach been applied to this
low quality of evidence, strong recommen-
dations against the drug would have been
made.
N Changing guideline recommendations
or their strength indicates inconsisten-
cy, a limitation of the framework
This is incorrect. Recommendations or
their strength, or both, are likely to
change if different grading frameworks
are used over time. Kavanagh demon-
strates this in his comparison of the SSC
guideline recommendations developed in
2004 with its 2008 update. Furthermore,
recommendations or their strength may
change with newer and higher quality of
evidence and with repeated more insight-
ful guideline panel deliberations even
with the use of one and the same
framework, such as GRADE. Also, dif-
ferent guideline panels may come up with
somewhat different strengths of recom-
mendations based on the same body of
evidence given variation in their clinical
and socioeconomic settings and popula-
tion of interest, and valued judgments. All
the above-mentioned should not be
grounds for claims that the GRADE is
an inherently inconsistent framework that
should be discarded.
In our view GRADE should be consid-
ered not an instrument for which reliabil-
ity and validity must be established but
rather as a systematic and transparent
framework generating recommendations
from available evidence as opposed to
recommendations originating in an unsys-
tematic and implicit ‘‘feel’’ for it. This
attribute of GRADE is a strong argument
in favour of using it as it lays the process of
translating evidence into recommenda-
tions open for scrutiny and criticism by
peers and consumers thereby increasing
public confidence in guidelines.
N GRADE-based recommendations, gen-
erated for specific population(s) and
clinical setting(s), are widely applica-
ble
We do not believe this to be true. As
recommendations are specific to popula-
tions and clinical, cultural, and socioeco-
nomic settings, they can be misapplied
when these qualifiers are not explicitly and
clearly linked to recommendations in
summary of guidelines. For example, a
recommendation of primary percutaneous
coronary intervention in the management
of acute myocardial infarction may be less
effective than thrombolytic therapy in
some developing countries where expertise
in and infrastructure for interventional
cardiology are lacking. As such, recom-
mendations of guideline panels in devel-
oped countries should not be blindly
adopted by developing countries without
a formal evaluation and vice versa.
N O n c eas t r o n gr e c o m m e n d a t i o n
against an intervention is made as per
the GRADE method, future research on
it will be stifled
We believe this is incorrect. Recom-
mendations based on the GRADE ap-
proach specifically apply to clinical and
not research settings. As long as there is a
reasonable rationale, future research on
the intervention can continue [13].
Finally, we think that the GRADE
framework needs continued discussion
and possibly revisions. However, currently
the framework is the best available ap-
proach to deal with the inherently implicit
subjectivity involved in translating.
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